New hope for hard-to-treat lymphoma: experimental drug takes on standard therapy
NCT ID NCT06122389
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tests a new drug called SHR2554 against an existing drug, chidamide, for people with a rare blood cancer (PTCL) that has returned or not responded to prior therapy. About 130 adults aged 18-70 will be randomly assigned to one of the two treatments. The main goal is to see if SHR2554 can delay cancer growth better than chidamide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PTCLT WITH AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.